FDA Initiates Class II Recall for Wuxi Medical Instrument Factory's ViaMed Alcohol Prep Pads Due to Sterility Concerns
Wuxi Medical Instrument Factory Co., Ltd. faces an FDA Class II recall for ViaMed Alcohol Prep Pads due to sterility assurance failures and cGMP deviations. This impacts Rece International Corp. and necessitates immediate supply chain review for sterile medical devices. Procurement and regulatory teams must assess exposure and reinforce supplier qualification protocols to mitigate risk.
FDA Mandates Class II Recall for Wuxi Medical Instrument Factory's Sterile Prep Pads
The U.S. Food and Drug Administration (FDA) has initiated a Class II recall, designated D-0247-2025, for ViaMed Alcohol Prep Pads manufactured by Wuxi Medical Instrument Factory Co., Ltd. in Wuxi, China. This voluntary, firm-initiated recall commenced on February 12, 2025, following critical observations of a lack of assurance of sterility and significant deviations from current Good Manufacturing Practices (cGMP) at the manufacturing site. For procurement directors, this event signals an immediate need to quarantine and return affected product lots, specifically 200830 (Exp 08/29/2025), 210925 (Exp 09/24/2026), and 221225 (Exp 12/24/2027), to mitigate patient safety risks and avoid regulatory penalties. Regulatory affairs heads must recognize that sterility failures and cGMP non-compliance are high-priority issues for the FDA, potentially leading to increased scrutiny on similar imported products. The recall of 37,500 boxes distributed in Florida underscores the direct commercial impact and the necessity for robust quality control throughout the supply chain, especially for products intended for external use where sterility is paramount to prevent infection.
Facility Profile: Wuxi Medical Instrument Factory's Role in US Supply
Wuxi Medical Instrument Factory Co., Ltd., located in Wuxi, China, serves as a manufacturer of medical instruments and supplies, including the ViaMed Alcohol Prep Pads (70% Isopropyl Alcohol). This facility's role is critical as a supplier to the U.S. market, specifically manufacturing for Rece International Corp. of Miami Lakes, Florida, which then distributes the product under NDC: 70006-500-01. For supply chain VPs, this incident highlights the inherent risks associated with reliance on overseas manufacturing facilities, particularly those in regions with varying regulatory oversight standards. The recall of a product like alcohol prep pads, a common consumable in healthcare settings, can lead to immediate supply disruptions for distributors like Rece International Corp. and their downstream customers. Business development executives should note that such events can create market opportunities for alternative suppliers who can demonstrate superior quality and compliance, while also serving as a cautionary tale regarding the due diligence required when vetting international manufacturing partners.
Supply Chain Exposure: Implications for Rece International Corp. and Distributors
The direct impact of this recall is most acutely felt by Rece International Corp., the Miami Lakes, Florida-based entity for whom Wuxi Medical Instrument Factory Co., Ltd. manufactures the ViaMed Alcohol Prep Pads. With 37,500 boxes distributed within Florida, Rece International Corp. faces immediate operational challenges, including managing product returns, communicating with affected customers, and securing alternative supply to maintain market presence. Procurement directors and supply chain VPs must assess their exposure to Wuxi Medical Instrument Factory Co., Ltd. and any other suppliers sourcing from this specific Chinese facility. This incident serves as a critical reminder to map out multi-tier supply chains to identify single points of failure and potential regulatory vulnerabilities. The FDA's focus on sterility assurance means that any product, including common consumables like alcohol prep pads, can trigger significant disruption if cGMP standards are not rigorously met. Proactive risk assessment and diversification of suppliers are essential to mitigate the commercial and reputational damage associated with such recalls.
Mitigating Risk: Strategies for Alternative Sourcing and Supplier Qualification
Given the recall of ViaMed Alcohol Prep Pads due to sterility and cGMP concerns, procurement teams must immediately review and fortify their sourcing strategies for sterile medical devices and consumables. While specific alternative suppliers are not named in the available intelligence, the imperative is to diversify the supplier base beyond single-origin manufacturers, particularly for high-volume, critical products like 70% Isopropyl Alcohol prep pads. Supply chain VPs should prioritize suppliers with established track records of FDA compliance and robust quality management systems, potentially exploring manufacturers in regions with stringent regulatory frameworks such as North America or Europe. Qualification timelines for new suppliers, especially for sterile products, can be extensive, often requiring comprehensive on-site audits, documentation review, and product validation. Business development executives might identify opportunities to partner with or acquire companies demonstrating strong compliance, thereby strengthening their market position. This incident underscores the necessity of moving beyond price-driven procurement to a value-based approach that heavily weights quality, regulatory adherence, and supply chain resilience.
Broader Regulatory Context: FDA's Focus on Sterility and cGMP Compliance
This Class II recall by Wuxi Medical Instrument Factory Co., Ltd. aligns with a broader trend of heightened FDA scrutiny on sterility assurance and cGMP adherence, particularly for pharmaceutical and medical device manufacturers operating internationally. While no specific prior regulatory history for Wuxi Medical Instrument Factory Co., Ltd. is available, this event mirrors other recent industry challenges. For instance, a parallel event in June 2026 involved Essential Wellness Pharma's Progesterone Injection facing a Class II recall due to similar sterility assurance failures. This pattern indicates that regulatory affairs heads must anticipate continued rigorous enforcement by the FDA regarding manufacturing quality, especially for sterile products. The agency's focus extends to all aspects of cGMP, from facility controls to process validation, emphasizing that even seemingly low-risk products like alcohol prep pads are subject to stringent quality requirements. Companies must ensure their quality systems are not only documented but also demonstrably effective in preventing contamination and ensuring product integrity.
Remediation Timeline and Future Regulatory Outlook for Wuxi Medical Instrument Factory
The recall of ViaMed Alcohol Prep Pads by Wuxi Medical Instrument Factory Co., Ltd. is currently ongoing, requiring the firm to implement comprehensive corrective and preventive actions (CAPAs) to address the identified cGMP deviations and sterility assurance failures. For regulatory affairs heads, the immediate priority for Wuxi Medical Instrument Factory Co., Ltd. will be to submit a detailed response to the FDA outlining their remediation plan, including root cause analysis, corrective actions taken at the Wuxi facility, and measures to prevent recurrence. Failure to adequately address these issues could lead to further FDA enforcement actions, potentially escalating to an Import Alert for products originating from the Wuxi facility, which would severely restrict their ability to supply the U.S. market. Supply chain VPs should prepare for potential long-term disruption from this supplier, necessitating a robust contingency plan. This event serves as a clear signal that the FDA maintains a vigilant stance on product quality and safety, especially for imported sterile medical products, compelling all manufacturers to uphold the highest cGMP standards.